Xcout Intel
Disc Medicine, Inc.
Based in Watertown, Massachusetts, Disc Medicine, Inc. operates as a clinical-stage biotechnology company. Its core mission involves the discovery, development, and commercialization of novel therapeutic solutions for individuals suffering from serious hematological diseases. The company is actively constructing a pipeline of drug candidates, designed to address a variety of these conditions by precisely targeting fundamental biological mechanisms related to red blood cell biology, particularly heme biosynthesis and iron homeostasis.
Subscribe to see Disc Medicine, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Disc Medicine, Inc. at a glance
Disc Medicine, Inc. is a biotechnology company headquartered in Watertown, United States. It is publicly listed (IRON) with a market capitalisation of $2.4B. Xcout tracks 25 named people at Disc Medicine, Inc., including John D. Quisel (Chief Executive Officer, President & Director). Xcout recorded 23 job postings from Disc Medicine, Inc. in the last 90 days.
Disc Medicine, Inc. leadership
- John D. QuiselChief Executive Officer, President & Director
- John QuiselChief Executive Officer
- Jean FranchiChief Financial Officer
- Rahul Rajan KaushikChief Technical Officer
- William Jacob SavageChief Medical Officer
- Pamela StephensonChief Commercial Officer
19 more named people on record for Disc Medicine, Inc., with roles, board committees and tenure — see the full roster →
Hiring at Disc Medicine, Inc.
Xcout recorded 23 job postings from Disc Medicine, Inc. in the last 90 days, from a hiring record Xcout has kept since June 2026.
The weekly hiring trend, the roles and locations behind it — see Disc Medicine, Inc.'s hiring signals →
Disc Medicine, Inc. competitors
A few of Disc Medicine, Inc.'s closest competitors — see the full list of competitors and alternatives →
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed to developing life-improving treatments for patients in the United States afflicted by genetically defined diseases with significant unmet medical needs. Its leading investigational therapies include losmapimod, a small molecule targeting facioscapulohumeral muscular dystrophy, and FTX-6058, an orally administered fetal hemoglobin inducer for sickle cell disease and related hemoglobinopathies, such as beta-thalassemia. Beyond these, Fulcrum is actively engaged in discovering new drug targets for various rare conditions, encompassing neuromuscular, muscular, central nervous system, and hematologic disorders, alongside cardiomyopathies and pulmonary diseases. The company has established key collaborations, notably a research and discovery partnership with Acceleron Pharma Inc. to identify biological targets within the pulmonary disease area, and a strategic licensing and development agreement with MyoKardia, Inc. focused on novel targeted therapies for genetic cardiomyopathies. Incorporated in 2015, Fulcrum Therapeutics, Inc. maintains its headquarters in Cambridge, Massachusetts.
Scarlet Therapeutics, founded in 2021 and headquartered in Bristol, United Kingdom, is developing a pioneering platform that generates novel red blood cell-based therapeutics to treat a wide range of diseases.
Sidero Bioscience is a clinical-stage biotechnology company that develops natural iron supplement products to address iron deficiency and nutritional health. Its proprietary SideroSorb platform and BioFe iron complex utilize a unique uptake mechanism designed to improve absorption and minimize gastrointestinal side effects compared to traditional iron therapies.
Ferrosa Therapeutics AG is a Swiss biotechnology company founded in Basel, Switzerland, focusing on developing novel therapeutics to treat anemia and related conditions.
Remix Therapeutics, Inc. is a biotechnology company headquartered in Watertown, Massachusetts. The company specializes in developing novel therapies that alter RNA processing to address serious diseases.
Get Disc Medicine, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Disc Medicine, Inc. in Xcout Intel
- 25 named people with titles, LinkedIn and board committees
- Weekly hiring history and the mix of roles behind it
- 1 corporate event with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access